The FDA accepted a supplemental new drug application for niraparib, treating women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status, based on data from the PRIMA study.
The FDA recently granted priority review to Takeda’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer.
With February being National Cancer Prevention Month, here are the latest updates in cancer prevention.
Therapy-associated polyposis was found to have similar features to various hereditary colorectal cancer symptoms, and recognition of it could have implications for cancer risk and screening among childhood and young adult cancer survivors.
Nurses were found to be significantly more likely to under-rate the nutritional status of their pediatric patients, suggesting the need for guidelines for nutritional assessment of children.
The FDA granted a priority review to selinexor oral tablets for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least 2 prior therapies.
The FDA granted breakthrough therapy designation to enfortumab vedotin based on results from the dose-escalation cohort and expansion cohort A of the phase Ib/II EV-103 trial.
Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.
The FDA granted a priority review to the new drug application for lurbinectedin as a treatment for patients with small cell lung cancer.